A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Inclusion Criteria: * Patient with histologically-confirmed, locally advanced or metastatic cancer who has progressed on standard therapy or for whom no standard therapy exists: * Part 1 (dose-escalation): solid tumours of any origin; * Part 2 (expansion): * Cohort A: Non-squamous non small cell lung cancer (non-squamous NSCLC); * Cohort B: Gynaecological cancers: ovarian cancer, endometrial cancer, cervical cancer; * Cohort C: Pancreatic adenocarcinoma (PA); * Cohort D: Uveal melanoma (UM). * c-MET prevalence confirmed by: * Part 1: Tumour c-MET positive membrane staining by immunohistochemistry (IHC) and/or MET amplification by dual In Situ Hybridization (dISH) and/or known MET-mutation; * Part 2: Tumour c-MET membrane expression by immunohistochemistry (IHC score ≥ 2+) as determined by the central laboratory on most recent available/obtained tumour material from a site not previously irradiated; * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1; * Adequate organ function Exclusion Criteria: * Having been treated with: * Trastuzumab duocarmazine (SYD985) at any time; * Other anticancer therapy within 4 weeks or as defined in the protocol; * History or presence of keratitis, glomerulonephritis, idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan; * History (within 6 months prior to start IMP) or presence of clinically significant cardiovascular disease such as unstable angina, congestive heart failure, myocardial infarction, uncontrolled hypertension, or cardiac arrhythmia requiring medication; * Symptomatic brain metastases, brain metastases requiring steroids or treatment for brain metastases within 8 weeks